{
  "item1": "Products treat variety conditions affecting spine, including degenerative disc disease, spinal deformity, spinal tumors, fractures spine, stenosis. These products include CATALYFT PL expandable interbody spacers, CD Horizon ModuLeX spinal system, T2 STRATOSPHERE expandable corpectomy system. These products can also include titanium interbody implants surface technologies, such Adaptix interbody system incorporated Titan interbody fusion device nanoLOCK technology. Products facilitate less invasive thoracolumbar surgeries, including CD Horizon Solera Voyager percutaneous fixation system various retractor systems access spine through smaller incisions.",
  "item7": "Contingent consideration Includes commitments related funding minority investments, estimated milestone payments, royalty obligations. While not certain if and/or when payments will made, maturity dates included table reflect best estimates. Includes inventory purchase commitments, research development, other arrangements legally binding specify minimum purchase quantities spending amounts. These purchase commitments do not exceed projected requirements normal course business.",
  "item2": "Six months ended October 25, 2024 (in millions, except per share data) Income Before Income Taxes Tax Provision (Benefit) Net Income attributable Medtronic GAAP Non-GAAP Adjustments: Amortization intangible assets Restructuring associated costs Acquisition divestiture-related items Certain litigation charges, net (Gain)/loss minority investments Medical device regulations Certain tax adjustments, net Company recognized $91 million accelerated amortization certain intangible assets within Cardiovascular Portfolio. charges primarily relate employee termination benefits facility related contract termination costs. charges primarily include business combination costs, changes fair value contingent consideration, exit business-related charges, gains related certain business asset sales. Exit business-related charges primarily relate impending separation Diabetes business costs associated Company's June 2021 decision stop distribution sale Medtronic HVAD System."
}